000309926 001__ 309926
000309926 005__ 20260219120951.0
000309926 0247_ $$2doi$$a10.1016/j.euo.2026.01.012
000309926 0247_ $$2pmid$$apmid:41702759
000309926 037__ $$aDKFZ-2026-00376
000309926 041__ $$aEnglish
000309926 082__ $$a610
000309926 1001_ $$aKlett, Maike K$$b0
000309926 245__ $$aExpanding Risk-adapted Early Detection of Prostate Cancer: A Call to Action for Men at High Risk.
000309926 260__ $$aAmsterdam$$bElsevier$$c2026
000309926 3367_ $$2DRIVER$$aarticle
000309926 3367_ $$2DataCite$$aOutput Types/Journal article
000309926 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771424793_2782105
000309926 3367_ $$2BibTeX$$aARTICLE
000309926 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309926 3367_ $$00$$2EndNote$$aJournal Article
000309926 500__ $$aepub
000309926 520__ $$aRisk-adapted prostate cancer screening is urgently needed to reduce overdiagnosis and overtreatment in the general population while allowing intensified risk adapted early detection in high-risk individuals. Clear eligibility criteria for genetic testing, professional education, and structured early detection programs must be established.
000309926 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000309926 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309926 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b1$$udkfz
000309926 7001_ $$aKibel, Adam$$b2
000309926 7001_ $$aLakes, Jale$$b3
000309926 7001_ $$aRana, Huma Q$$b4
000309926 7001_ $$aSerzan, Michael$$b5
000309926 7001_ $$aKarger, André$$b6
000309926 7001_ $$aMorgans, Alicia K$$b7
000309926 773__ $$0PERI:(DE-600)2945338-0$$a10.1016/j.euo.2026.01.012$$gp. S2588931126000362$$pnn$$tEuropean urology oncology$$vnn$$x2588-9311$$y2026
000309926 909CO $$ooai:inrepo02.dkfz.de:309926$$pVDB
000309926 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000309926 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000309926 9141_ $$y2026
000309926 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL ONCOL : 2022$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-05
000309926 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR UROL ONCOL : 2022$$d2025-11-05
000309926 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000309926 980__ $$ajournal
000309926 980__ $$aVDB
000309926 980__ $$aI:(DE-He78)C130-20160331
000309926 980__ $$aUNRESTRICTED